Efficacy, safety and tolerability of sildenafil in Brazilian hypertensive patients on multiple antihypertensive drugs

Albuquerque, Denílson Campos de; Miziara, Lineu José; Saraiva, José Francisco Kerr; Rodrigues, Ulisses S.; Ribeiro, Artur Beltrame; Wajngarten, Maurı́cio

doi:10.1590/s1677-55382005000400008

Cited by 14 publications

(9 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, many antihypertensive drugs may worsen sexual function as a drug specific side effect [9]. Although some clinical studies have observed similar efficacy of PDE5Is regardless of the number of antihypertensive agents [10–12], it is still probable that significant hypertension and its treatment would cause reduced efficacy of PDE5Is. One of Korean clinical trial indicated relatively lower success rates for restoration of erectile function in those who had four or more antihypertensive agents [13].…”

Section: Introductionmentioning

confidence: 99%

“…Hemodynamic studies with other PDE5Is revealed minor changes, which are not likely to be clinically significant, and modest side effect profiles during the concomitant use of various antihypertensive agents, except in the case of alpha antagonists and nitrate donors [14,15]. Also, recent clinical trials were incomplete to report increased incidence of treatment‐emergent adverse events (TEAEs) after the treatment with PDE5Is in those receiving antihypertensive agents [10–13].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Efficacy and Safety of Udenafil [Zydena] for the Treatment of Erectile Dysfunction in Hypertensive Men Taking Concomitant Antihypertensive Agents

Paick

Kim

Park

et al. 2009

The Journal of Sexual Medicine

View full text Add to dashboard Cite

Introduction Erectile dysfunction (ED) and hypertension are frequent comorbid conditions. The vasodilating properties of type 5 phosphodiesterase inhibitor (PDE5I) are the major concerns for the treatment of ED patients on antihypertensive medications. Aim To evaluate the efficacy and safety of Udenafil [Zydena] (Dong-A, Seoul, Korea), a newly developed PDE5I, for the treatment of ED patients on antihypertensive medication. Methods It was a multicentered, randomized, double-blind, placebo-controlled, fix-dosed clinical trial among 165 ED patients receiving antihypertensive medications. The subjects treated with placebo, 100 mg or 200 mg of Udenafil for 12 weeks were asked to complete the Sexual Encounter Profile (SEP) diary, the International Index of Erectile Function (IIEF), and the Global Assessment Question (GAQ) during the study period. Main Outcome Measures Primary parameter: the change from baseline for IIEF erectile function domain (EFD) score; Secondary parameters: the IIEF Question 3 and 4, SEP Question 2 and 3, the rate of achieving normal erectile function (EFD ≥ 26) and the response to GAQ. Results Compared to placebo, patients receiving both doses of Udenafil showed significantly improved the IIEF-EFD score. The least squares means for the change from baseline in IIEF-EFD scores were 8.4 and 9.8 for 100 mg and 200 mg Udenafil groups, respectively; those values were significantly higher than that of placebo (2.4, P < 0.0001). Similar results were observed in the comparison of Q3 and Q4 of IIEF, SEP diary and GAQ. Headache and flushing were the most common treatment-emergent adverse events, which were transient and mild-to-moderate in nature. No parameters of efficacy and safety were affected among the subsets stratified according to either the number of antihypertensive medication received or the previous experience of PDE5Is treatment. Conclusion Udenafil significantly improved erectile function among ED patients with hypertensive symptom treated with concomitant antihypertensive medication. The treatment did not increase the frequency or severity of adverse events.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The Efficacy and Safety of Udenafil [Zydena] for the Treatment of Erectile Dysfunction in Hypertensive Men Taking Concomitant Antihypertensive Agents

Paick

Kim

Park

et al. 2009

The Journal of Sexual Medicine

View full text Add to dashboard Cite

show abstract

“…They are efficacious and well tolerated for the treatment of ED in men with comorbidities, such as hypertension, depression, congestive heart failure, cardiovascular disease, dyslipidemia, diabetes, and BPH/LUTS, as demonstrated in double‐blind, placebo‐controlled (DBPC) trials [56–74]. Furthermore, oral PDE5 inhibitors, including sildenafil [75–77], tadalafil [78], and vardenafil [79], are effective in men with ED who were being treated with antihypertensive medication, and DBPC trials support the role of sildenafil and tadalafil in the treatment of antidepressant‐associated ED [80–83]. In addition to these results in men with ED, sildenafil treatment was effective in the treatment of SSRI‐associated ejaculatory delay in an open‐label trial [84].…”

Section: Impact Of Psychological Correlates Of Ed On Adherencementioning

confidence: 94%

Erectile Dysfunction Diagnosis and Treatment as a Means to Improve Medication Adherence and Optimize Comorbidity Management

Scranton¹,

Goldstein

Stecher

2013

The Journal of Sexual Medicine

View full text Add to dashboard Cite

Introduction Optimal pharmacologic management of diseases comorbid with erectile dysfunction (ED), such as cardiovascular disease, depression, diabetes, dyslipidemia, hypertension, and benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS), is dependent upon long-term treatment compliance and may be complicated by poor adherence to medication use. ED may contribute to poor adherence to medication use because poor quality erectile function may be an unwanted adverse effect of antihypertensives, antidepressants, and 5-α reductase inhibitors for treatment of BPH/LUTS. Diminished erectile spontaneity, rigidity, and/or sustaining capability also negatively affects mood, self-esteem, and confidence, which compromise motivation to be compliant with medications that treat diseases comorbid with ED. Aim Literature review was performed to explore the role of ED diagnosis and effective treatment in enhancing overall management of selected ED comorbidities, highlighting the role of medication adherence. Methods Several PubMed searches were performed. Results Diagnosis and successful treatment of concomitant ED may promote improved adherence and management of comorbid diseases. Concomitant ED management may improve treatment outcome, decrease healthcare costs, and possibly prevent or even improve deterioration in medical conditions comorbid with ED. Because ED is a silent marker and predictor of comorbidities, especially cardiovascular disease, earlier diagnosis of ED may provide an opportunity to prevent future cardiovascular events. In men presenting with complaints of ED, screening for, monitoring, and appropriately treating diseases that are comorbid with ED is essential. Screening for and appropriately treating ED is important for enhanced life quality and improved motivation in men with existing ED comorbidities or risk factors. Conclusions Appropriate management of ED and its risk factors may have beneficial effects on diseases that are comorbid with ED, and vice versa, most likely via shared pathophysiological pathways. Clinicians may need to consider men's health overall, of which sexual health is a central component, in order to provide optimal disease management.

show abstract

“…In patients undergoing hemodialysis, or who have recurrence of prostate cancer after radiation therapy and are undergoing surgery, with poor response to oral medications, the prosthesis is a good treatment option (2)(3)(4).…”

Section: Introductionmentioning

confidence: 99%

“…With the technical improvement of the prosthesis, there was a marked decrease in the number of complications and revision surgeries that patients experienced, thereby increasing the popularity and use of this therapeutic option (5,6). Today, there are over 30,000 penile prostheses implanted per year, with most of these surgeries being performed in North America (4).…”

Section: Introductionmentioning

confidence: 99%

Penile prosthesis implantation in an academic institution in Latin America

et al. 2010

View full text Add to dashboard Cite

Purpose: We performed a retrospective study to analyze the effectiveness of implantable penile prostheses in the treatment of erectile dysfunction. Results: Approximately half of patients had previously used oral drugs before implantation of the prosthesis. About 45% had diabetes, 25.9% had previously undergone radical prostatectomy (RP), and 64% had hypertension. Exchange was performed in 5.7% for fracture, inadequate size, or extrusion. A total of 24.5% of men had immediate postoperative pain, 7.9% had local infection, and 8.6% had other complications. Patients who had previously undergone RP were 3.2 times more likely to experience a postoperative complication than patients who had not (p = 0.061). Eighty-nine (64%) patients returned to having sex as they had before being diagnosed with ED. Ninety-two of the men (66.2%) had sexual intercourse one to two times per week. One hundred twenty patients (86.3%) rated their level of satisfaction as good, excellent or very good, which was similar to the percentage of partners. The mean follow-up was 40 months. Conclusion: Higher rates of postoperative infections and mechanical problems with the implant were found in this study as compared to other studies, which was probably associated with the relative lack of experience of the trainees who were performing the surgeries. Patients with a history of RP or diabetes mellitus prior to implantation were at higher risk of postoperative complications.

show abstract

Efficacy, safety and tolerability of sildenafil in Brazilian hypertensive patients on multiple antihypertensive drugs

Abstract: Sildenafil is efficacious and safe for the treatment of hypertensive patients with ED who receive concurrent combinations of anti-hypertensive drugs.

Cited by 14 publications

References 26 publications

The Efficacy and Safety of Udenafil [Zydena] for the Treatment of Erectile Dysfunction in Hypertensive Men Taking Concomitant Antihypertensive Agents

The Efficacy and Safety of Udenafil [Zydena] for the Treatment of Erectile Dysfunction in Hypertensive Men Taking Concomitant Antihypertensive Agents

Erectile Dysfunction Diagnosis and Treatment as a Means to Improve Medication Adherence and Optimize Comorbidity Management

Penile prosthesis implantation in an academic institution in Latin America

Contact Info

Product

Resources

About